Wall Street brokerages expect that scPharmaceuticals Inc. (NASDAQ:SCPH – Get Rating) will report earnings per share (EPS) of ($0.33) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for scPharmaceuticals’ earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.29). scPharmaceuticals reported earnings per share of ($0.26) during the same quarter last year, which suggests a negative year over year growth rate of 26.9%. The business is expected to issue its next earnings report on Monday, January 1st.
On average, analysts expect that scPharmaceuticals will report full-year earnings of ($1.51) per share for the current year, with EPS estimates ranging from ($1.62) to ($1.37). For the next year, analysts anticipate that the business will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.50) to ($0.73). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for scPharmaceuticals.
scPharmaceuticals (NASDAQ:SCPH – Get Rating) last announced its quarterly earnings results on Monday, May 16th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08.
SCPH opened at $5.02 on Wednesday. The company has a 50-day moving average of $5.23 and a 200-day moving average of $4.99. The company has a market capitalization of $137.40 million, a P/E ratio of -4.78 and a beta of 0.43. scPharmaceuticals has a 1-year low of $3.48 and a 1-year high of $7.28. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.27 and a current ratio of 4.81.
In other news, major shareholder 5Am Partners Iv, Llc sold 270,000 shares of the stock in a transaction on Monday, April 11th. The shares were sold at an average price of $5.00, for a total transaction of $1,350,000.00. Following the transaction, the insider now owns 120,966 shares in the company, valued at approximately $604,830. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.08% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Advisor Group Holdings Inc. increased its stake in shares of scPharmaceuticals by 980.4% during the 3rd quarter. Advisor Group Holdings Inc. now owns 3,857 shares of the company’s stock worth $25,000 after purchasing an additional 3,500 shares during the last quarter. Sandy Cove Advisors LLC bought a new stake in shares of scPharmaceuticals during the 4th quarter worth $53,000. Envestnet Asset Management Inc. boosted its holdings in shares of scPharmaceuticals by 20.4% during the 4th quarter. Envestnet Asset Management Inc. now owns 12,882 shares of the company’s stock worth $65,000 after buying an additional 2,186 shares during the period. IPG Investment Advisors LLC bought a new stake in shares of scPharmaceuticals during the 4th quarter worth $72,000. Finally, Thomasville National Bank bought a new stake in shares of scPharmaceuticals during the 4th quarter worth $75,000. Institutional investors own 72.84% of the company’s stock.
About scPharmaceuticals (Get Rating)
scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.
- Get a free copy of the StockNews.com research report on scPharmaceuticals (SCPH)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.